Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + Apatinib in Recurrent Platinum-resistant Ovarian Cancer
NCT04068974Phase 2Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Oct 2019
- Primary completion
- Jun 2021
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab and Rivoceranib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Peking Union Medical College Hospital. Primary endpoint: Objective Response Rate up to 2 years. Status: unknown.
02
Drugs
camrelizumabRivoceranib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT04068974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04068974.